Next Generation Protein Therapeutics & Bioconjugates Summit is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Mike Schopperle, PhD
CEO at CureMeta


Mike Schopperle received a Ph.D. in Biochemistry from Brandeis University and followed with postdoctoral studies in cancer research at Beth Israel Deaconess Medical Center, and an Instructor faculty position at Harvard Medical School to continue cancer stem cell research. In 2011 he founded CureMeta, a start-up biotech which focuses on novel diagnostics and therapeutics for aggressive and metastatic cancers.

Mike Schopperle, PhD's Network

Agenda Sessions

  • Development of Antibody-Drug-Conjugates to Novel Embryonic Targets in Cancer

    , 2:45pm
  • PANEL DISCUSSION: Identifying New Targets

    , 11:00am